CAG
BIO icon

Csenge Advisory Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Csenge Advisory Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-427
Closed -$211K – 610
2022
Q2 		$211K Sell
427
-54
-11% -$28.1K 0.02% 530
2022
Q1 		$271K Buy
481
+29
+6% +$17.5K 0.02% 520
2021
Q4 		$297K Buy
452
+1
+0.2% +$748 0.03% 455
2021
Q3 		$335K Sell
451
-1
-0.2% -$749 0.03% 446
2021
Q2 		$297K Sell
452
-5
-1% -$3.04K 0.03% 456
2021
Q1 		$275K Buy
457
+17
+4% +$10.1K 0.03% 407
2020
Q4 		$256K Sell
440
-34
-7% -$19.4K 0.03% 358
2020
Q3 		$253K Buy
474
+31
+7% +$15.7K 0.03% 327
2020
Q2 		$200K Buy
+443
New +$195K 0.03% 357
2018
Q4 		– Sell
-30
Closed -$8K – 345
2018
Q3 		$8K Buy
+30
New +$9.31K ﹤0.01% 539

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Csenge Advisory Group's BIO Position: Q3 2022 in Review

Csenge Advisory Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 427 shares — an estimated $211K sold.

Csenge Advisory Group first reported a position in BIO in Q3 2018 and held it in 10 quarters. The position peaked at $335K in Q3 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Csenge Advisory Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Csenge Advisory Group sold 427 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $211K.
  • Csenge Advisory Group first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and held it in 10 quarters.
  • Csenge Advisory Group's Bio-Rad Laboratories Class A position peaked at $335K in Q3 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Csenge Advisory Group's 13F filing for Q3 2022, filed 4 Oct 2022.